Micronised purified flavonoid fraction: a phlebotropic agent that is useful in the treatment of chronic venous insufficiency and venous ulcer

2003 ◽  
Vol 19 (11) ◽  
pp. 1-4
Author(s):  
&NA;
1999 ◽  
Vol 14 (4) ◽  
pp. 151-157 ◽  
Author(s):  
W. Gliński ◽  
B. Chodynicka ◽  
J. Roszkiewicz ◽  
T. Bogdanowski ◽  
B. Lecewicz-Toruń ◽  
...  

Objective: To determine the increase in healing rate of venous ulcer in patients receiving a micronised purified flavonoid fraction (MPFF) as supplementation to standard local care. Design: A randomised, open, controlled, multicentre study. Setting: Departments of Dermatology and University Outpatients Clinics. Patients: One hundred and forty patients with chronic venous insufficiency and venous ulcers. Intervention: Patients received standard compressive therapy plus external treatment alone or 2 tablets of MPFF daily in addition to the above treatment for 24 weeks. Main outcome measure: Healing of ulcers and their reduction in size after 24 weeks of treatment. Results: The percentage of patients whose ulcers healed completely was found to be markedly higher in those receiving MPFF in addition to standard external and compressive treatment than in those treated with conventional therapy alone (46.5% vs 27.5%; p<0.05, OR = 2.3, 95% CI 1.1–4.6). Ulcers with diameters <3 cm were cured in 71% of patients in the MPFF group and in 50% of patients in the control group, whereas ulcers between 3 and 6 cm in diameter were cured in 60% and 32% of patients ( p<0.05), respectively. The mean reduction in ulcer size was also found to be greater in patients treated with MPFF (80%) than in the control group (65%) ( p<0.05). The cost-effectiveness ratio (cost per healed ulcer) in the MPFF group was €1026.2 compared with €1871.8 in the control group. Conclusions: These results indicate that MPFF significantly improves the cure rate in patients with chronic venous insufficiency.


1996 ◽  
Vol 57 (10) ◽  
pp. 757-766 ◽  
Author(s):  
Henri Boccalon ◽  
Catherine Salvadori ◽  
Dominique Benedittini ◽  
Dominique Steru ◽  
Claire Vilain

2011 ◽  
Vol 26 (5) ◽  
pp. 197-202 ◽  
Author(s):  
J T Christenson ◽  
C Prins ◽  
G Gemayel

Objective Increased intramuscular and subcutaneous tissue pressures are often found in patients with severe chronic venous insufficiency venous ulcer disease. Additional subcutaneous para-tibial fasciotomy promotes early ulcer healing. This study evaluates the mid-term effect of eradication of superficial reflux with additional fasciotomy in patients with increased tissue pressures. Method Between January 2006 and June 2009, 58 patients underwent fasciotomy. Tissue pressures (intramuscular and subcutaneous) were measured. Sixty-nine limbs with 91 venous ulcers were treated. Mean duration of the venous ulcer was 3.4 years. Underlying disease was post-thrombotic syndrome (PT) in 19 patients (33%, 24 limbs, 27 ulcers) and non-post-thrombotic (non-PT) severe chronic venous insufficiency in 39 (67%, 45 limbs, 64 ulcers). All patients were C6 at the time of surgery. Preoperative tissue pressures were 23.5 ± 6.1 mmHg (intramuscularly) and 9.8 ± 3.2 mmHg (subcutaneously). Results Ninety ulcers (99%) healed postoperatively (42 with and 48 without skin grafting). Tissue pressures significantly decreased following surgery and remained low at three months postoperatively. Ten ulcers in six patients recurred six to 20 months postoperatively (11%), resulting in 86.4 actuarial freedom from venous ulcer recurrence at three years following surgery. Four patients (1 non-PT and 3 PT) had re-fasciotomy; all healed initially but two ulcers (2 patients, PT) recurred at 11 and 12 months. Those patients underwent re-fasciotomy, one healed and one recurred six months later. Conclusion Eradication of superficial reflux with additional subcutaneous fasciotomy for chronic and recurrent venous ulcer improves ulcer healing or success of skin grafting. Mid-term results are excellent particularly in patients with non-PT disease. Recurrence is more frequently seen in patients with PT syndrome. In patients with ulcer recurrence and high tissue pressures, re-fasciotomy can be helpful to promote healing, particularly in patients with primary venous disease.


2021 ◽  
Vol 11 (1) ◽  
pp. 87-91
Author(s):  
Vladimir Izosimov ◽  
Serhiy Hryvenko ◽  
Yuriy Baranovskiy ◽  
Yuriy Artemov ◽  
Andrej Dovgan ◽  
...  

The article presents a clinical assessment of the effectiveness of the author's method of pharmacological correction in the complex treatment of patients with trophic ulcers of venous origin in the lower extremities. Based on the analysis of the data obtained, we found that the use of the proposed method of drug correction in the complex treatment of chronic venous ulcer ensures the effectiveness of treatment, a reduction in the duration of inpatient treatment, and the reliability of rehabilitation in the postoperative period.


2020 ◽  
Vol 19 (4) ◽  
pp. 2592
Author(s):  
H. M. Kurginyan ◽  
V. V. Raskin

The high prevalence of varicose veins has been established in numerous population studies. Currently, guidelines have been developed for the treatment of patients with varicose veins for various stages of chronic venous insufficiency. Nevertheless, despite the use of modern drugs, leg compression, surgical and other interventions, it is not possible to completely reverse the symptoms of venous insufficiency. The article is devoted to the analysis of micronized flavonoid purified fraction. The development of modern drugs for chronic venous diseases is an important direction in medicine. The creation of a drug pool manufactured InRussiais a priority in the development of the country’s pharmaceutical industry. The review presents data on the study of Detravenol (Russia), which is a combination of diosmin and hesperidin (micronized purified flavonoid fraction).


Author(s):  
M. N. Kudykin

The article presents up-to-date information about epidemiology, pathogenesis and clinical manifestations of chronic venous diseases and chronic venous insufficiency of the lower extremities. It discusses the mechanism of action of various phlebotrophic drugs intended for the treatment of symptoms of chronic venous diseases and chronic venous insufficiency and describes the advantages of micronized purified flavonoid fraction for the treatment of all clinical classes of chronic venous diseases.


Sign in / Sign up

Export Citation Format

Share Document